AstraZeneca beefs up cell therapy tool kit with gene editing deal

Katherine Lewin

News Reporter

AstraZeneca is licensing Revvity’s gene-editing technology in a non-exclusive agreement for an undisclosed amount in order to create cell therapies for the treatment of cancer …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca beefs up cell therapy tool kit with gene editing deal

Katherine Lewin

News Reporter

Sign up to read this article for free.

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

China’s biotech market is staging a comeback that US biotech can only wish for

Large vaccine makers stand by their investments despite US headwinds

With aims to become a 'generational biotech,' Zealand Pharma hires Lilly veteran as science chief

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

Genentech vet launches ADC startup with $20M

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

As­traZeneca beefs up cell ther­a­py tool kit with gene edit­ing deal

News Reporter

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

AstraZeneca beefs up cell therapy tool kit with gene editing deal